Gidazepam 3 mg Pellets Product Description

Introduction

Gidazepam is an atypical benzodiazepine derivative known for its selective anxiolytic effects with a comparatively lower risk of dependence. It acts as a prodrug to an active metabolite that modulates GABA receptors, producing calming and anxiolytic effects. Gidazepam 3 mg pellets offer a standardized solid dosage form for accurate dosing in research studies focused on benzodiazepine pharmacodynamics and CNS activity.

Chemical Properties and Specifications

2.1 Structural and Molecular Characteristics

• Chemical Formula: C17H15BrN4O2

• Molecular Weight: 387.23 g/mol

• CAS Number: 129186-29-4

• IUPAC Name: 1-(hydrazinocarbonyl)methyl-7-bromo-5-phenyl-1,2-dihydro-3H-1,4-benzodiazepine-2-one

• Synonyms: Gidazepam, Hydazepam, Hidazepam, Gidasepam

2.2 Physical Properties and Pellet Specifications

• Appearance: White to off-white solid pellets

• Dosage: 3 mg Gidazepam per pellet

• Purity: Typically ≥98% research or pharmaceutical grade

• Solubility: Soluble in DMSO and organic solvents; low water solubility

• Storage Recommendations: Store in airtight containers at -20°C, away from moisture and light to maintain long-term stability

Pharmacological Profile and Mechanism of Action

3.1 Mechanism of Action

Gidazepam itself acts as a prodrug, converting in the body to desalkylgidazepam, which is an agonist of GABA-A receptors that enhance inhibitory neurotransmission. This results primarily in anxiolytic effects with additional muscle relaxant and sedative properties. Its selective receptor activity reduces risks of tolerance and dependence compared to traditional benzodiazepines.

3.2 Research Applications

Used in CNS pharmacology and neuropharmacological research focusing on anxiolytic mechanisms, receptor binding, and CNS modulation. The pellet form permits reproducible dosing essential for experimental consistency.

Comparative Analysis with Related Compounds

4.1 Comparison with Other Benzodiazepines

Gidazepam differs from classic benzodiazepines by its prodrug status and selective anxiolytic profile. It presents lower dependence liability and a longer half-life relative to many conventional benzodiazepines, making it valuable in studies requiring prolonged anxiolytic effects.

4.2 Advantages for Research

Standardized pellets reduce dosing variability and enable precise administration. The 3 mg dose is suitable for various research protocols, including dose-response and chronic dosing studies.

Safety and Handling Guidelines

5.1 Laboratory Safety

Wear appropriate PPE: gloves, lab coat, eye protection. Handle in well-ventilated areas or fume hoods. Prevent inhalation and skin contact.

5.2 Disposal and Environmental Considerations

Dispose of according to hazardous chemical waste protocols in compliance with regulatory guidelines.

5.3 Regulatory Status

Gidazepam is a controlled research chemical. Use is restricted to regulated laboratory settings under legal compliance.

Frequently Asked Questions (FAQs)

1. What is the dosage in each pellet?
   3 mg Gidazepam.

2. What is Gidazepam’s molecular formula?
   C17H15BrN4O2.

3. What are the main effects?
   Anxiolytic, muscle relaxant, mild sedative.

4. What is its mechanism of action?
   Acts as a prodrug to GABA-A receptor agonist metabolite.

5. How should pellets be stored?
   Airtight containers, cool, dry, and protected from light.

Conclusion

Gidazepam 3 mg pellets provide a high purity, potent anxiolytic benzodiazepine prodrug dosage form for precise research dosing. Their stability and effectiveness make them ideal in neuropharmacological and CNS-focused investigations.